As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.
Services & Conditions

Conditions and Treatments

View Alphabetically

Find a Doctor
Advanced Doctor Search >

Octavio Vega, MDAt the end of the visit, my goal is to have the patients feel more informed and to feel like their issues have been properly addressed.

— Octavio Vega, MD, internist

Patricia Graham, MDI enjoy the challenges of piecing together the puzzle – putting difficult, complicated signs and symptoms together and trying to formulate a diagnosis.

— Patricia Graham, MD, internist

Hear more from doctors at Rush.

Patients & Visitors

Patients

Directions and Parking

Locations
Health & Wellness

Health News and Advice to Fit Your Life

The choices you make each day can have a huge effect on your health. Rush offers a wealth of resources to help you make good ones.

5 Things You Can Do to Prevent CancerMan riding bike on beachHow you can devise a cancer prevention action plan.

Combating Social Media DysmorphiaWoman washing carrots in sinkHow to love yourself — and your selfies — without filters or fillers.

 

About Us

Translate

French German Italian Portuguese Russian

Treatment Study for Recurrent Platinum-Resistant Ovarian Cancer

Clinical Trial Title: 
The OVAL study: A randomized, controlled, double-arm, double blind, multi-center study of ofranergene obadenovec (VB-111) combined with paclitaxel vs. paclitaxel combined with placebo for the treatment of recurrent platinum-resistant ovarian cancer.
Clinical Trial Protocol ID: 
17062008
Clinical Trial Investigator Name: 
Summer B. Dewdney, MD
Clinical Trial Protocol Description: 

The purpose of this phase 3, randomized, multi-center study is to compare VB-111 and paclitaxel to placebo and paclitaxel in adult patients with recurrent platinum-resistant ovarian cancer.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are a female patient at least 18 years of age.
  • Have histologically confirmed epithelial ovarian cancer and documented disease.
  • Have platinum-resistant disease
  • Have disease that is measurable according to RECIST 1.1 and require chemotherapy treatment.

You will be excluded from the study if any of the following criteria apply to you:

  • Have non-epithelial tumors (Carcino-sarcomas are excluded).
  • Have ovarian tumors with low malignant potential (i.e. borderline tumors) clear cell carcinomas, grade 1 serous tumors or mucinous tumors.
  • Have a history of other clinically active malignancy within 5 years of enrollment, except for tumors with a negligible risk for metastasis or death, such as adequately controlled basal-cell carcinoma, adequately controlled, non-metastatic squamous-cell carcinoma of the skin, or carcinoma in situ of the cervix or breast.
  • Have had previous ovarian cancer treatment with >5 anticancer regimens.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Gynecologic Cancers
Contact Phone: 
(312) 942-2417
Contact Name: 
Lois Winkelman